This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Scarpello, J. H. Search for Related Content Social Bookmarking                         What's this?

Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes

Department of Diabetes and Endocrinology, City General Hospital, Stoke on Trent, ST4 6QG, UK, jhbscarpello{at}hotmail.com

Recently revised consensus targets for glycaemic management in patients with type 2 diabetes are challenging and require optimisation of dosing strategies for oral antidiabetic therapies. The demonstration of significant cardiovascular outcome benefits in metformin-treated type 2 diabetic patients enrolled in the United Kingdom Prospective Diabetes Study has established this agent as the first line oral therapy after diet failure in newly presenting overweight people with type 2 diabetes mellitus. The antihyperglycaemic efficacy of metformin increases with increasing daily doses between 500 mg and the upper limits of the recommended daily dosage ( 2000 mg/day). Although metformin is associated with gastrointestinal side-effects in up to 20% of patients, this is not generally dose related. Transient dose reduction, slower titration and taking the dose with meals may ameliorate the problem. Risk of lactic acidosis due to metformin is negligible when this agent is prescribed correctly, and is unrelated to the plasma metformin concentration. Intensification of metformin therapy within the dose range represents a rational and practical therapeutic strategy for optimising glycaemic control in patients who are suitable for, and tolerant of, metformin treatment. The recently introduced 1000 mg metformin tablet should facilitate the use of higher doses and may help treatment compliance.

Key Words: metformin • oral antidiabetic therapy • type 2 diabetes • dose-response relationships.

The British Journal of Diabetes & Vascular Disease, Vol. 1, No. 1, 28-36 (2001)
DOI: 10.1177/14746514010010010501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. H. Scarpello and H. C. Howlett Metformin therapy and clinical uses Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 157 - 167. [Abstract] [PDF]

				J. A Ray, D. Huet, W. J Valentine, A. J Palmer, N. Cugnardey, and C. Renaudin Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance(R)) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting The British Journal of Diabetes & Vascular Disease, January 1, 2008; 8(1): 39 - 44. [Abstract] [PDF]

				M. D Feher, M. Al-Mrayat, J. Brake, and K. S. Leong Tolerability of prolonged-release metformin (Glucophage(R) SR) in individuals intolerant to standard metformin -- results from four UK centres The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 225 - 228. [Abstract] [PDF]